Evidence map›Paper›PMID 39532364›Full record

ArticleBMJ open2024

Effectiveness evaluation of an organisational intervention, targeting pregnancy and addiction care professionals, among women who have just given birth in maternity wards and smoked tobacco during pregnancy (5A-QUIT-N): study protocol for a stepped-wedge cluster randomised trial.

Charlotte Kervran, Florence Francis-Oliviero, Marion Kret, Adrianna Burtin, Rebecca Ratel, Estelle Clet, Fidéline Collin, Séverine Martiren, Claire Brandet, Judith Martin-Fernandez and 7 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Charlotte KervranINSERM, Bordeaux population Health, U1219, I-prev/PHARES, Equipe Labellisée Ligue Contre le Cancer, Université de Bordeaux, Talence, France charlotte.kervran@u-bordeaux.fr.ORCID http://orcid.org/0000-0003-0108-1079
Florence Francis-OlivieroPôle de santé publique, Service d'Information Médicale, CHU de Bordeaux, Bordeaux, France.ORCID http://orcid.org/0000-0002-5435-5064
Marion KretUSMR, CHU de Bordeaux, Bordeaux, France.ORCID http://orcid.org/0009-0003-9982-3903
Adrianna BurtinINSERM, Bordeaux population Health, U1219, I-prev/PHARES, Equipe Labellisée Ligue Contre le Cancer, Université de Bordeaux, Talence, France.ORCID http://orcid.org/0000-0002-8027-2174
Rebecca RatelINSERM, Bordeaux population Health, U1219, I-prev/PHARES, Equipe Labellisée Ligue Contre le Cancer, Université de Bordeaux, Talence, France.
Estelle CletINSERM, Bordeaux population Health, U1219, I-prev/PHARES, Equipe Labellisée Ligue Contre le Cancer, Université de Bordeaux, Talence, France.ORCID http://orcid.org/0000-0002-4767-5967
Fidéline CollinDRCI, CHU de Bordeaux, Bordeaux, France.ORCID http://orcid.org/0000-0002-2224-9339
Séverine MartirenService d'information médicale, Pôle de santé publique, CHU de Bordeaux, Bordeaux, France.
Claire BrandetCHU de Bordeaux, Bordeaux, France.
Judith Martin-FernandezISPED, Chaire Prévention, Université de Bordeaux, Talence, France.ORCID http://orcid.org/0000-0002-7380-5497
Sarah PerrinISPED, Chaire Prévention, Université de Bordeaux, Talence, France.ORCID http://orcid.org/0000-0002-4488-6689
Carla MoninINSERM, Bordeaux population Health, U1219, I-prev/PHARES, Equipe Labellisée Ligue Contre le Cancer, Université de Bordeaux, Talence, France.ORCID http://orcid.org/0009-0003-9216-4546
Linda CambonINSERM, Bordeaux population Health, U1219, I-prev/PHARES, Equipe Labellisée Ligue Contre le Cancer, Université de Bordeaux, Talence, France.ORCID http://orcid.org/0000-0001-6040-9826
Marc AuriacombeAddiction Psychiatry, Laboratoire SANPSY, CNRS UMR 6033, University of Bordeaux, Bordeaux, France.ORCID http://orcid.org/0000-0002-8938-8683
Loïc SentilhesDepartment of Gynaecology Obstetrics, University Hospital Centre Bordeaux, Bordeaux, France.ORCID http://orcid.org/0000-0003-0009-3625
François AllaService de prévention, CHU de Bordeaux, Bordeaux, France.ORCID http://orcid.org/0000-0002-5793-7190
5A-QUIT-N Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn 2021, among French women who smoked when they knew they were pregnant, 59% still smoked at the end of pregnancy. Support for pregnant women to stop smoking must include a structured organisational perspective. The main objective of the study is to evaluate the effectiveness of the 5A-QUIT-N organisational intervention on smoking cessation at delivery among pregnant women who smoke during pregnancy. METHODS AND ANALYSIS: The overarching goal of the 5A-QUIT-N intervention, which aims to organise the healthcare professionals monitoring pregnancy, specialists in addiction and tobacco use, and clinical and training tools, using the 5As method. The 5A-QUIT-N intervention will be evaluated in a pragmatic stepped-wedge cluster randomised trial. Within each cluster, during the 6 months before (control) and after (intervention) the intervention, women who smoke tobacco during pregnancy will be enrolled during their maternity stay after delivery. A transition period is planned between the control and intervention periods to deploy the intervention. All participating women will be interviewed using a heteroquestionnaire to assess smoking cessation, tobacco use monitoring by healthcare professionals and individual factors associated with tobacco use during pregnancy. The primary outcome was the point prevalence of abstinence at delivery, which is the proportion of women reporting abstinence from smoking for at least 7 days at delivery. 4200 women who smoked tobacco during pregnancy will be recruited over the entire study period (33 months) to evaluate the effectiveness. An estimated 4585 participants will be included for all aims. ETHICS AND DISSEMINATION: The study will be implemented in accordance with French regulations. The study including the consent process has been independently reviewed and approved by the French ethical board 'CPP Ile de France I' on 10 February 2022 (No CPPIDF1-2022-DI08-cat.2). The results will be disseminated on various academic and non-academic platforms. The results will be reported in international peer-reviewed journals and presented at international and national conferences.

Indexed as

Smoking CessationAdultFemaleFranceHealth PersonnelHumansPragmatic Clinical Trials as TopicPregnancyPregnancy ComplicationsRandomized Controlled Trials as TopicTobacco SmokingOrganisation of health servicesPregnancyPsychosocial InterventionRandomized Controlled TrialTobacco Use

Identifiers

PMID39532364
PMCPMC11575246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.